Christine Parseghian

Clinical trials

• Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

  Principal investigator · Recruiting · Phase 2

  M.D. Anderson Cancer Center

  2025–2029
• A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

  Principal investigator · Recruiting · Phase 1, Phase 2

  M.D. Anderson Cancer Center

  2024–2029
• Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

  Principal investigator · Recruiting · Phase 1

  M.D. Anderson Cancer Center

  2024–2028
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

  Principal investigator · Active not recruiting · Phase 1, Phase 2

  M.D. Anderson Cancer Center

  2020–2028